| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kai-Kai Huang, Shan-Shan Han, Li-Ya He, Lin-Lin Yang, Bao-Ying Liang, Qing-Yu Zhen, Zi-Bo Zhu, Cai-Yun Zhang, Hong-Yi Li and Ying Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases |
2018B030322012 |
|
| Corresponding Author |
Ying Lin, MD, Chief Physician, Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. lin19791226@gzucm.edu.cn |
| Key Words |
Toxic epidermal necrolysis; Toripalimab; Lenvatinib; Programmed cell death-1 inhibitor; Liver cancer; Case report |
| Core Tip |
Both programmed cell death-1 (PD-1) inhibitors and lenvatinib, which exhibit a synergistic effect, are promising drugs for tumor treatment. However, we encountered a patient who presented with erythema, blisters and erosions on the face, neck, trunk and limbs 1 wk after combination therapy with lenvatinib and toripalimab, a PD-1 inhibitor. Skin biopsy was performed, and the diagnosis was confirmed as toxic epidermal necrolysis (TEN). We are the first group to report the occurrence of TEN, a grade 4 toxicity, after this combination therapy. Full-dose and long-term corticosteroids were administered, and the rashes gradually faded. |
| Publish Date |
2022-04-08 12:06 |
| Citation |
Huang KK, Han SS, He LY, Yang LL, Liang BY, Zhen QY, Zhu ZB, Zhang CY, Li HY, Lin Y. Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report. World J Clin Cases 2022; 10(11): 3478-3484 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i11/3478.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i11.3478 |
